{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:53:55Z","timestamp":1780581235611,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.seminhematol.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T03:45:27Z","timestamp":1528170327000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study\u204e"],"prefix":"10.1053","volume":"55","author":[{"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sgherza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"D'Adda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Auteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Ibatici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Trawinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-4595","authenticated-orcid":false,"given":"Giampietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto M.","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.B.","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Catani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1053\/j.seminhematol.2018.05.013_bib0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2018.05.013_bib0002","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2018.05.013_bib0003","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"New Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2018.05.013_bib0004","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2018.05.013_bib0005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1053\/j.seminhematol.2018.05.013_bib0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2018.05.013_bib0007","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: a user's manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1053\/j.seminhematol.2018.05.013_bib0008","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2018.05.013_bib0009","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/modpathol.2013.109","article-title":"Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2018.05.013_bib0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2018.05.013_bib0011","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2018.05.013_bib0012","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.05.013_bib0013","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2018.05.013_bib0014","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2018.05.013_bib0015","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2018.05.013_bib0016","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2018.05.013_bib0017","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2017.297","article-title":"Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis","volume":"32","author":"Hernandez-Boluda","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2018.05.013_bib0018","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.05.013_bib0019","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2018.05.013_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2018.05.013_bib0021","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2018.05.013_bib0022","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","article-title":"Does ruxolitinib prolong the survival of patients with myelofibrosis?","volume":"129","author":"Cervantes","year":"2017","journal-title":"Blood"},{"issue":"45","key":"10.1053\/j.seminhematol.2018.05.013_bib0023","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminhematol.2018.05.013_bib0024","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.05.013_bib0025","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2018.05.013_bib0026","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.05.013_bib0027","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"33","key":"10.1053\/j.seminhematol.2018.05.013_bib0028","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2018.05.013_bib0029","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.3324\/haematol.2016.149013","article-title":"Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera\/essential thrombocytosis myelofibrosis","volume":"101","author":"Gowin","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2018.05.013_bib0030","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:25:58Z","timestamp":1758522358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196318300258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0037196318300258"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.013","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study\u204e","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}